MA60223B1 - Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol - Google Patents

Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol

Info

Publication number
MA60223B1
MA60223B1 MA60223A MA60223A MA60223B1 MA 60223 B1 MA60223 B1 MA 60223B1 MA 60223 A MA60223 A MA 60223A MA 60223 A MA60223 A MA 60223A MA 60223 B1 MA60223 B1 MA 60223B1
Authority
MA
Morocco
Prior art keywords
compositions
systems
methods
acting
drug delivery
Prior art date
Application number
MA60223A
Other languages
English (en)
Inventor
David Lechuga-Ballesteros
Vidya JOSHI
James ARCHBELL
Kellisa LACHACZ
Charina LAMPA
Lauren MELLO
Gertrude GUTIERREZ
Penny Tan
Michael Riebe
Original Assignee
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=82748203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA60223(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Pharmaceuticals Lp filed Critical Astrazeneca Pharmaceuticals Lp
Publication of MA60223B1 publication Critical patent/MA60223B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions, des méthodes et des systèmes permettant une administration, par voie pulmonaire, de principes actifs par l'intermédiaire d'un aérosol doseur. Dans certains modes de réalisation, les compositions comprennent un milieu de suspension de HFO-1234ze (E), des particules d'agent actif et des particules de suspension. Les particules d'agent actif peuvent comprendre un, deux, trois ou quatre agents actifs choisis parmi un antagoniste muscarinique à action prolongée (LAMA), des agonistes β2 à action prolongée (LABA), des agonistes β à action courte (SABA), un corticostéroïde inhalé (ICS), et un agent anti-inflammatoire non corticostéroïdien.
MA60223A 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol MA60223B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163220362P 2021-07-09 2021-07-09
US202163282356P 2021-11-23 2021-11-23
PCT/US2022/036543 WO2023283439A1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol
EP22748656.0A EP4175619B1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol

Publications (1)

Publication Number Publication Date
MA60223B1 true MA60223B1 (fr) 2024-06-28

Family

ID=82748203

Family Applications (3)

Application Number Title Priority Date Filing Date
MA60224A MA60224B1 (fr) 2021-07-09 2022-07-08 Compositions, méthodes et systèmes pour l'administration d'un médicament en aérosol
MA60223A MA60223B1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol
MA61888A MA61888B1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration de médicament en aérosol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA60224A MA60224B1 (fr) 2021-07-09 2022-07-08 Compositions, méthodes et systèmes pour l'administration d'un médicament en aérosol

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA61888A MA61888B1 (fr) 2021-07-09 2022-07-08 Compositions, procédés et systèmes pour l'administration de médicament en aérosol

Country Status (28)

Country Link
US (5) US20240252440A1 (fr)
EP (6) EP4393478A3 (fr)
JP (3) JP2024525555A (fr)
KR (3) KR20240042436A (fr)
AU (3) AU2022305962A1 (fr)
CA (3) CA3226557A1 (fr)
CL (3) CL2024000041A1 (fr)
CO (3) CO2024000631A2 (fr)
CR (3) CR20240064A (fr)
DK (3) DK4197528T3 (fr)
DO (3) DOP2024000004A (fr)
EC (1) ECSP24011022A (fr)
ES (3) ES2983201T3 (fr)
FI (3) FI4175620T3 (fr)
HR (3) HRP20240716T1 (fr)
HU (3) HUE067283T2 (fr)
IL (3) IL309888A (fr)
LT (3) LT4175619T (fr)
MA (3) MA60224B1 (fr)
MX (3) MX2024000465A (fr)
PE (3) PE20240807A1 (fr)
PL (3) PL4197528T3 (fr)
PT (3) PT4175619T (fr)
RS (3) RS65598B1 (fr)
SI (3) SI4175620T1 (fr)
SM (3) SMT202400370T1 (fr)
TW (3) TW202317079A (fr)
WO (3) WO2023283439A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250345292A1 (en) * 2022-04-28 2025-11-13 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma
CN116270464B (zh) * 2023-03-01 2025-09-30 深圳市贝美药业有限公司 一种克立硼罗气雾剂及其制备方法
FR3150798B1 (fr) 2023-07-07 2025-11-21 Aptar France Sas Dispositif de distribution de produit fluide
WO2025179277A1 (fr) 2024-02-23 2025-08-28 Zelicovich Marcelo Lazaro Système de distribution d'aérosol à suspension d'air améliorée
TW202600144A (zh) * 2024-02-23 2026-01-01 瑞典商阿斯特捷利康公司 Copd之三重組合療法
WO2026006658A1 (fr) * 2024-06-27 2026-01-02 Lupin Inc. Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
US20260007598A1 (en) * 2024-07-05 2026-01-08 Honeywell International Inc. Compositions, devices and methods for respritory delivery of active pharmaceutical ingredients
GB202410910D0 (en) * 2024-07-25 2024-09-11 Bespak Europe Ltd Method of filling a pressurised dispensing container and filled pressurised dispensing container
US12496272B1 (en) 2024-07-31 2025-12-16 Amphastar Pharmaceuticals, Inc. Stable epinephrine suspension formulation for inhalation with HFO propellant
US12383516B1 (en) 2025-01-06 2025-08-12 Amphastar Pharmaceuticals, Inc. Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37872A (en) 1863-03-10 Improved mast-hoop
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (fr) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
NZ500555A (en) 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
NZ518401A (en) 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
SI3170880T1 (sl) 2002-10-25 2020-07-31 Honeywell International Inc. Uporaba sestavkov, ki kot hladilni sestavek vsebujejo HFO-1234ZE ali HFO-1234YF
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
CA2669924A1 (fr) * 2006-11-20 2008-05-29 Cipla Limited Dispositif aerosol
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
SG181870A1 (en) * 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
RU2013155903A (ru) * 2011-05-17 2015-06-27 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
CN104080770A (zh) 2011-11-09 2014-10-01 迈兰实验室有限公司 用于制备罗氟司特的改进方法
CN107596518B (zh) * 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
WO2014060464A1 (fr) 2012-10-17 2014-04-24 Interquim, S.A. Procédé de préparation de roflumilast
HUE052275T2 (hu) * 2013-01-28 2021-04-28 Incozen Therapeutics Pvt Ltd Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával
US20150150787A1 (en) * 2013-05-22 2015-06-04 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
ES2970740T3 (es) 2017-10-09 2024-05-30 Pearl Therapeutics Inc Unidad de administración de aerosol

Also Published As

Publication number Publication date
JP2024527348A (ja) 2024-07-24
FI4197528T3 (fi) 2024-05-24
TW202317079A (zh) 2023-05-01
PT4175620T (pt) 2024-06-21
AU2022305962A1 (en) 2024-01-25
US20240325298A1 (en) 2024-10-03
DOP2024000004A (es) 2024-04-15
WO2023283439A1 (fr) 2023-01-12
SI4175620T1 (sl) 2024-08-30
HUE067281T2 (hu) 2024-10-28
CO2024000631A2 (es) 2024-02-15
TW202317080A (zh) 2023-05-01
CA3226557A1 (fr) 2023-01-12
IL309888A (en) 2024-03-01
HRP20240753T1 (hr) 2024-09-13
LT4175619T (lt) 2024-06-10
DK4175619T3 (da) 2024-05-06
EP4366695A1 (fr) 2024-05-15
HUE067547T2 (hu) 2024-10-28
KR20240042436A (ko) 2024-04-02
US20240252440A1 (en) 2024-08-01
MX2024000465A (es) 2024-04-05
PE20240808A1 (es) 2024-04-18
PT4175619T (pt) 2024-06-06
PL4175619T3 (pl) 2024-08-05
HRP20240725T1 (hr) 2024-08-30
JP2024525567A (ja) 2024-07-12
DOP2024000006A (es) 2024-04-15
TW202317081A (zh) 2023-05-01
IL309907A (en) 2024-03-01
EP4393477A3 (fr) 2024-09-11
DOP2024000005A (es) 2024-04-15
ES2981514T3 (es) 2024-10-09
CL2024000039A1 (es) 2024-08-16
PL4197528T3 (pl) 2024-08-12
EP4175620B1 (fr) 2024-04-10
CR20240064A (es) 2024-09-02
KR20240042438A (ko) 2024-04-02
PL4175620T3 (pl) 2024-08-05
WO2023283441A1 (fr) 2023-01-12
AU2022306682A1 (en) 2024-01-25
CO2024000748A2 (es) 2024-02-26
MA61888B1 (fr) 2024-06-28
WO2023283438A1 (fr) 2023-01-12
MA60224B1 (fr) 2024-06-28
SI4175619T1 (sl) 2024-08-30
AU2022308837A1 (en) 2024-01-25
CO2024000742A2 (es) 2024-02-26
US20240252432A1 (en) 2024-08-01
SMT202400368T1 (it) 2024-11-15
ES2983201T3 (es) 2024-10-22
DK4197528T3 (da) 2024-05-06
SI4197528T1 (sl) 2024-08-30
HUE067283T2 (hu) 2024-10-28
EP4175620A1 (fr) 2023-05-10
CL2024000041A1 (es) 2024-08-16
ECSP24011022A (es) 2024-03-01
CR20240063A (es) 2024-04-25
CL2024000037A1 (es) 2024-08-16
US20230026203A1 (en) 2023-01-26
EP4393477A2 (fr) 2024-07-03
CR20240066A (es) 2024-04-12
DK4175620T3 (da) 2024-06-03
EP4175619B1 (fr) 2024-04-10
IL309908A (en) 2024-03-01
RS65537B1 (sr) 2024-06-28
KR20240042437A (ko) 2024-04-02
FI4175620T3 (fi) 2024-06-25
MX2024000467A (es) 2024-04-05
SMT202400312T1 (it) 2024-09-16
EP4197528A1 (fr) 2023-06-21
JP2024525555A (ja) 2024-07-12
FI4175619T3 (fi) 2024-05-28
ES2981709T3 (es) 2024-10-10
PE20241067A1 (es) 2024-05-13
EP4393478A2 (fr) 2024-07-03
EP4393478A3 (fr) 2024-09-11
SMT202400370T1 (it) 2024-11-15
RS65598B1 (sr) 2024-06-28
MX2024000468A (es) 2024-04-05
PE20240807A1 (es) 2024-04-18
EP4175619A1 (fr) 2023-05-10
EP4197528B1 (fr) 2024-04-03
LT4197528T (lt) 2024-06-10
CA3226153A1 (fr) 2023-01-12
CA3226155A1 (fr) 2023-01-12
RS65597B1 (sr) 2024-06-28
LT4175620T (lt) 2024-06-25
HRP20240716T1 (hr) 2024-08-30
PT4197528T (pt) 2024-06-06
US20240358662A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
MA60223B1 (fr) Compositions, procédés et systèmes pour l'administration d'un médicament en aérosol
Daley‐Yates et al. Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression
Han et al. CYP3A‐mediated drug–drug interaction potential and excretion of brentuximab vedotin, an antibody− drug conjugate, in patients with CD30‐positive hematologic malignancies
Markham Fostamatinib: first global approval
Matthews et al. Safety, tolerability, and pharmacokinetics of single‐and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV
Wijeyeratne et al. Anti‐platelet therapy: ADP receptor antagonists
Zhang et al. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance
Peterson et al. Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice
Rodvold et al. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents
Scott Selexipag: first global approval
Huang et al. Investigation of basolateral targeting micelles for drug delivery applications in polycystic kidney disease
Shah et al. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers
Nishiyama et al. Chapter 2: indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
Cha et al. Sustained Increase in the Oral Bioavailability of Loperamide after a Single Oral Dose of HM 30181, a P‐glycoprotein Inhibitor, in Healthy Male Participants
Mehraj et al. Effects of statins beyond lipid-lowering agents in ART-treated HIV infection
Vogelmeier et al. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
Fowler et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel CRTH2 antagonist BI 1021958 at single oral doses in healthy men and multiple oral doses in men and women with well‐controlled asthma
Ahn et al. Pharmacokinetic–pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects
Sethi et al. Efficacy of formoterol fumarate delivered by metered dose inhaler using Co-Suspension™ Delivery Technology versus Foradil® Aerolizer® in moderate-to-severe COPD: a randomized, dose-ranging study
Norris et al. Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2‐agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers
Jimenez et al. Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
AR126412A1 (es) Composiciones, métodos y sistemas para la administración de fármacos en aerosol
Kamal et al. Future of drug discovery
Boffito et al. Pharmacology lessons from chemoprophylaxis studies
Miller et al. Randomized dose-ranging study of a budesonide metereddose inhaler by using co-suspension delivery technology in asthma.